Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: Diagnostic and biological implications

Modern Pathology

Volumn 15, Issue 12, 2002, Pages 1294-1301

  Rorive, Sandrine ^a   Eddafali, Brahim ^a   Fernandez, Sergio ^a   Decaestecker, Christine ^b   André, Sabine ^c   Kaltner, Herbert ^c   Kuwabara, Ichiro ^d   Liu, Fu Tong ^d   Gabius, Hans Joachim ^c   Kiss, Robert ^b   Salmon, Isabelle ^a  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenoma; Carcinoma; Cytokeratin 19; Diagnosis; Galectin 7; Quantitative immunohistochemistry; Thyroid

Indexed keywords

CYTOKERATIN 19; GALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 7; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; CELL MATURATION; CELL PROLIFERATION; COMPUTER ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; NONHUMAN; OVARY FOLLICLE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; RAT; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR DIAGNOSIS;

ADENOMA; CARCINOMA; DISEASE PROGRESSION; GALECTINS; GOITER; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; THYROID GLAND; THYROID NEOPLASMS;

EID: 18744413873     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000037306.19083.28     Document Type: Article

References (60)

1. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996;56:5309-18.
2. Gabius HJ. Concepts of tumor lectinology. Cancer Invest 1997;15:454-64.
3. Brockhausen I, Schutzbach J, Kuhns W. Glycoproteins and their relationship to human disease. Acta Anat (Basel) 1998;161:36-78.
4. Perillo NL, Marcus ME, Baum LG. Galectins: Versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998;76:402-12.
5. Gabius HJ. Glycohistochemistry: The why and how of detection and localization of endogenous lectins. Anat Histol Embryol 2001;30:3-31.
6. Lahm H, Andre S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, et al. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 2001;127:375-86.
7. Cooper DNW. Galectinomics: Finding themes in complexity. Biochim Biophys Acta 2002;1572:209-31.
8. Rabinovich GA, Rubinstein N, Toscano M. Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta 2002 (in press).
9. Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta 2002;1572:285-93.
10. Kopitz J, von Reitzenstein C, Andre S, Kaltner H, Uhl J, Ehemann V, et al. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 2001;276:35917-23.
11. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, et al. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 2002;50:392-401.
12. Itzkowitz SH. Galectins: Multipurpose carbohydrate-binding proteins implicated in tumor biology. Gastroenterology 1997;113:2003-5.
13. Ohannesian DW, Lotan R. Galectins in tumor cells. In: Gabius HJ, Gabius S, editors. Glycosciences: Status and Perspectives. Weinheim: Chapman & Hall; 1997. p. 459-9.
14. André S, Kojima S, Yamazaki N, Fink C, Kaltner H, Kayser K, et al. Galectins-1 and -3 and their ligands in tumor biology. J Cancer Res Clin Oncol 1999;125:461-74.
15. Chiariotti L, Berlingieri MT, Battaglia C, Benvenuto G, Martelli ML, Salvatore P, et al. Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer 1995;64:171-5.
16. Xu XC, El-Naggar AK, Lotan R. Differentiated expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic information. Am J Pathol 1995;147;815-22.
17. Fernandez PL, Merino MJ, Gomez M, Campo E, Medina T, Castronovo V, et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 1997;181:80-6.
18. Orlandi F, Sagglorato E, Pivano G, Puligheddu B, Termine A, Cappia S, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998;58:3015-20.
19. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida JI, Hattori K, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999;85:2475-84.
20. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 1999;17:3494-502.
21. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 2000;31:428-33.
22. Nagy N, Decaestecker C, Dong X, Kaltner H, Schüring MP, Rocmans P, et al. Characterization of ligands for galectins, natural galactoside-binding immunoglobulin G subfractions and sarcolectin and also of the expression of calcyclin in thyroid lesions. Histol Histopathol 2000;15:503-13.
23. Saggiorato E, Cappia S, De Giuli P, Mussa A, Pancani G, Caraci P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5152-8.
24. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-50.
25. Cvejic D, Savin S, Paunovic I, Tatic S, Havelka M, Sinadinovic J. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer Res 1998;18:2637-41.
26. Niedobitek C, Niedobitek F, Lindenberg G, Bachler B, Neudeck H, Zuschneid W, et al. Untersuchungen zur expression von galectin-3 im schilddrüsengewebe und in follikelzelltumoren der schilddrüse. Pathologe 2001;22:205-13.
27. Madsen P, Rasmussen HH, Flint T, Gromov P, Kruse TA, Honore B, et al. Cloning, expression, and chromosome mapping of human galectin-7. J Biol Chem 1995;270:5823-9.
28. Magnaldo T, Bernerd F, Darmon M. Galectin-7, a human 14-kDa S-Jectin, specifically expressed in keratinocytes and sensitive to retinoic acid. Dev Biol 1995;168:259-71.
29. Magnaldo T, Fowlis D, Darmon M. Galectin-7, a marker of all types of stratified epithelia. Differentiation 1998;63:159-68.
30. Timmons PM, Coinot C, Cail I, Poirier F, Magnaldo T. Expression of galectin-7 during epithelial development coincides with the onset of stratification. Int J Dev Biol 1999;43:229-35.
31. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, et al. Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation. Cancer Res 1997;57:4111-7.
32. Lu J, Pei H, Kaeck M, Thompson HJ. Gene expression changes associated with chemically induced rat mammary carcinogenesis. Mol Carcinog 1997;20:204-15.
33. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389:300-5.
34. Bernerd F, Sarasin A, Magnaldo T. Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocytes. Proc Natl Acad Sci U S A 1999;96:11329-34.
35. Kuwabara I, Kuwabara Y, Yang RY, Schuler M, Green DR, Zuraw BL, et al. Galectin-7 (PIGI) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome C release. J Biol Chem 2002;277:3487-97.
36. Miettinen M, Kovatich AJ, Karkkainen P. Keratin subsets In papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications. Virchows Arch 1997;431:407-13.
37. Baloch ZW, Abraham S, Roberts S, LiVolsi VA. Differential expression of cytokeratins in follicular variant of papillary carcinoma: An immunohistochemical study and its diagnostic utility. Hum Pathol 1999;30:1166-71.
38. Hirokawa M, Carney JA, Ohtsuki Y. Hyalinizing trabecular adenoma and papillary carcinoma of the thyroid gland express different cytokeratin patterns. Am J Surg Pathol 2000;24:877-81.
39. Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: A note of caution. Am J Clin Pathol 2001;116:696-702.
40. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, et al. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 2001;11:12-26.
41. Rorive S, Belot N, Decaestecker C, Lefranc F, Gordower L, Micik S, et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 2001;33:241-55.
42. Salmon I, Gasperin P, Pasteels JL, Heimann R, Kiss R. Relationship between histopathologic typing and morphonuclear assessments of 238 thyroid lesions. Am J Clin Pathol 1992;97:776-86.
43. Salmon I, Gasperin P, Remmelink M, Rahier I, Rocmans P, Pasteels JL, et al. Ploidy level and proliferative activity measurements in a series of 407 thyroid tumors or other pathologic conditions. Hum Pathol 1993;24:912-20.
44. Hedinger C, Williams ED, Sobin LH. Histological Typing of Thyroid Tumors. World Health Organization International Histological Classification of Tumors. 2nd Ed. Springer-Verlag; 1988.
45. LiVolsi VA. Surgical pathology of the thyroid. In: Bennington JL, editor. Major Problems in Pathology. Vol. 22. Philadelphia: WB Saunders; 1990. p. 173-212.
46. Wynforth-Thomas D, Williams ED. Thyroid Turnouts. Molecular Basis of Pathogenesis. New York: Churchill Livingstone, 1989.
47. Andre S, Pieters RJ, Vrasidas I, Kaltner H, Kuwabara I, Liu FT, et al. Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxiclusters, and cell surface glycoconjugates. Chembiochem 2001;2:822-30.
48. Gabius HJ. Influence of type of linkage and spacer on the interaction of beta-galactoside-binding proteins with immobilized affinity ligands. Anal Biochem 1990;189:91-4.
49. Thompson LD, Wieneke JA, Paal E, Frommelt RA, Adair CF, Heffess CS. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 2001;91:505-24.
50. Oertel YL, Oertel JE. Diagnosis of malignant epithelial thyroid lesions: Fine needle aspiration and histopathologic correlation. Ann Diagn Pathol 1998;2:377-400.
51. Nagy N, Camby I, Decaestecker C, Chaboteaux C, Gras T, Darro F, et al. The influence of L-triiodothyronine, L-thyroxine, estradiol-17β, the luteinizing hormonereleasing hormone, the epidermal growth factor and gastrin on cell proliferation in organ cultures of 35 benign and 13 malignant human thyroid tumors. J Cancer Res Clin Oncol 1999;125:361-8.
52. Chiariotti L, Berlingieri MT, De Rosa P, Battaglia C, Berger N, Bruni CB, et al. Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. Oncogene 1992;7:2507-11.
53. Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, Nomura T, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 2001;18:787-92.
54. Gunnersen JM, Spirkoska V, Smith PE, Danks RA, Tan SS. Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia 2000;32:146-54.
55. Yamaoka K, Mishima K, Nagashima Y, Asai A, Sanai Y, Kirino T. Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J Neurosci Res 2000;59:722-30.
56. Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, et al. Galectin-1 modulates human glioblastoma cell migration into the brain though modifications to the actin cytoskeleton and the levels of expression of small GTP-ases. J Neuropathol Exp Neurol 2002;61:585-96.
57. Yamaoka K, Ohno S, Kawasaki H, Suzuki K. Overexpression of a beta-galactoside binding protein causes transformation of BALB3T3 fibroblast cells. Biochem Biophys Res Commun 1991;179:272-9.
58. Adams L, Scott GK, Weinberg CS. Biphasic modulation of cell growth by recombinant human galectin-1. Biochim Biophys Acta 1996;1312:137-44.
59. Gabius HJ. Probing, the cons and pros of lectin-induced immunomodulation: Case studies for the mistletoe lectin and galectin-1. Biochimie 2001;83:659-66.
60. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001;20:7486-93.